High doses of lithium aspartate reduced the severity of postcoccygeal syndrome
A randomized clinical trial showed that administration of lithium aspartate at doses of 10 to 15 milligrams per day for three weeks did not result in significant improvement in post-ovid fatigue or cognitive dysfunction. That said, a follow-up dose-fitting study showed that lithium aspartate at a dose of 40 to 45 milligrams per day in an open-label form resulted in significant improvement in post-ovoid symptoms. However, only three people participated in the high-dose study, and they knew they were taking lithium aspartate. The study is published in JAMA Network Open.
Previously, in a study by one of the authors of this paper, Thomas Guttuso of the State University of New York at Buffalo, 9 out of 10 patients with neurological manifestations of postcovicular syndrome reported improvement after 3-5 days after starting 5-10 milligrams of lithium aspartate per day. In the new work, beneficial effects were observed in three patients, with two individuals with blood lithium concentrations of 0.18 and 0.49 milliequivalents per liter showing greater effects than the third, who had a blood lithium concentration of 0.1 milliequivalents per liter.